Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation

Abstract Background Rivaroxaban is an oral anticoagulant approved in the US for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). We determined the effectiveness and associated risks of rivaroxaban versus other oral anticoagulants in a large real-wo...

Full description

Bibliographic Details
Main Authors: Faye L. Norby, Lindsay G.S. Bengtson, Pamela L. Lutsey, Lin Y. Chen, Richard F. MacLehose, Alanna M. Chamberlain, Ian Rapson, Alvaro Alonso
Format: Article
Language:English
Published: BMC 2017-09-01
Series:BMC Cardiovascular Disorders
Subjects:
Non-valvular atrial fibrillation
Stroke
Warfarin
Dabigatran
Rivaroxaban
Online Access:http://link.springer.com/article/10.1186/s12872-017-0672-5

Internet

http://link.springer.com/article/10.1186/s12872-017-0672-5

Similar Items